The Food and Drug Administration has approved Lembaz, an injection that is the first treatment shown to help patients with infantile-onset Niemann-Pick disease type C live longer, the agency announced Tuesday.

In the data behind the approval, patients treated with Lembaz had a 55 percent lower risk of death than comparable untreated patients, with a median survival of 8.5 years against 4.9 years. The drug is approved for adults and children weighing at least 7 kilograms (about 15 pounds) whose neurological symptoms began before age six.

A disease with almost no options

Niemann-Pick type C is a lysosomal storage disorder affecting about one in 150,000 people, in which the body cannot move cholesterol and other fats out of its cells. The disease progressively damages the brain and nervous system; children with the infantile form lose motor and cognitive abilities and, until now, no treatment had been shown to change how long they live. Two therapies were approved earlier, but neither had been shown to reduce the risk of death.

The approval went to Mandos LLC, a subsidiary of Beren Therapeutics PBC. Lembaz's active ingredient, adrabetadex, is designed to pull trapped cholesterol out of cells — attacking the buildup that drives the disease rather than only its symptoms.

“Lembaz is the first product shown to help NPC patients live longer.”— The FDA, announcing the approval

Acting FDA Commissioner Kyle Diamantas called the approval more than a regulatory milestone for families facing the disease. The drug, developed by Mandos LLC, had received the agency's Breakthrough Therapy designation.

Approved without a classic trial

With so few patients, the evidence came from 36 people across three studies and an expanded-access program, compared against matched external controls rather than a randomized placebo group. The drug is injected into the spinal canal every two weeks.

It carries a boxed warning — the FDA's strongest — for hearing damage, including permanent deafness.

What Happens Next

The company expects Lembaz to be available at initial treatment sites in early December. Watch how insurers handle a first-of-its-kind rare-disease drug, and whether longer follow-up confirms the survival advantage the FDA acted on.